BT
BTEE.LSE iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
- USD
No recent price
- Total assets
- 28.9M
- Expense ratio
- 0.34%
- Dividend yield
- 0.21%
- 1-year return
- +36.59%
- Holdings
- 248
- Since
- 2018
Fund data as reported by the issuer, updated Nov 3, 2026. Total assets are in the fund's base currency.
What does BTEE.LSE invest in?
Tracks Morningstar Gbl Biotechnology NR USD- Mostly US stocks (98.7%)
- Largest sector: Healthcare (100.0%)
- Largest region: North America (91.6%)
- Top 3 holdings: 25.9% of the fund
Asset allocation
- US stocks 98.7%
- Non-US stocks 5.0%
- Cash 0.2%
Top holdings
- Gilead Sciences Inc 9.33%
- Amgen Inc 8.83%
- Vertex Pharmaceuticals Inc 7.73%
- Regeneron Pharmaceuticals Inc 6.20%
- Moderna Inc 5.78%
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) performance
Sharpe ratio 1.19- This year
- +26.57%
- 1 year
- +36.59%
- 3 years
- +23.92%
- 5 years
- +7.88%
Volatility 16.4% over 1 year and 17.4% over 3 years. Moderate, similar to a broad stock index.
Total returns in the fund's currency as reported by the issuer; past returns do not predict future returns. Volatility is the yearly standard deviation of returns. Ask AI to explain these numbers
BTEE.LSE price
Prices on the chart can differ slightly from the closing prices StockSummer shows.
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) top holdings
48.7% of the fund| Holding | Sector | Country | Weight |
|---|---|---|---|
| Gilead Sciences Inc GILD.US | Healthcare | United States | 9.33% |
| Amgen Inc AMGN.US | Healthcare | United States | 8.83% |
| Vertex Pharmaceuticals Inc VRTX.US | Healthcare | United States | 7.73% |
| Regeneron Pharmaceuticals Inc REGN.US | Healthcare | United States | 6.20% |
| Moderna Inc MRNA.US | Healthcare | United States | 5.78% |
| Revolution Medicines Inc RVMD.US | Healthcare | United States | 2.54% |
| Biogen Inc BIIB.US | Healthcare | United States | 2.44% |
| Illumina Inc ILMN.US | Healthcare | United States | 2.28% |
| Royalty Pharma Plc RPRX.US | Healthcare | United States | 1.88% |
| Roivant Sciences Ltd ROIV.US | Healthcare | United States | 1.71% |
The 10 largest of 248 holdings.
BTEE.LSE sector exposure
- Healthcare100.0%
Share of the stocks in the fund.
BTEE.LSE regional exposure
- North America91.6%
- Europe Developed2.2%
- United Kingdom2.0%
- Asia Emerging0.1%
- Australasia0.0%
- Africa/Middle East0.0%
- Asia Developed0.0%
Share of the stocks in the fund.
Company size
Average market cap 27.5B- Mega cap0.6%
- Big cap26.2%
- Medium cap35.5%
- Small cap25.7%
- Micro cap10.8%
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) fund profile
- Fund name
- iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
- Ticker
- BTEE.LSE
- Exchange
- London Exchange
- Index tracked
- Morningstar Gbl Biotechnology NR USD
- Category
- Healthcare Equity
- Domicile
- Ireland
- Inception date
- Mar 5, 2018
- Trading currency
- USD
- Expense ratio
- 0.34%
- Dividends paid
- Half-yearly